Mixed Connective Tissue Disease

📋 Key Information Summary

📋

Definition: Mixed Connective Tissue Disease (MCTD) is an immune-mediated overlap syndrome defined by high-titre anti-U1-RNP antibodies and clinical features of SLE, systemic sclerosis (SSc), and polymyositis/dermatomyositis (IIM).
Core antibody: High-titre anti-U1-RNP (nucleolar pattern on ANA) is mandatory for diagnosis and often precedes clinical features.
Cardinal features: Raynaud phenomenon (nearly universal), swollen "puffy" hands (sausage digits), sclerodactyly, myalgia/arthritis, and oesophageal dysmotility.
Most feared complication: Pulmonary arterial hypertension (PAH) is the leading cause of death; annual screening is mandatory.
Key differential: Differentiate from undifferentiated CTD (UCTD) by the presence of anti-U1-RNP and specific multi-system overlap features.
Management: Base treatment on dominant phenotype (e.g., SSc-like for Raynaud/PAH, SLE-like for arthritis, IIM-like for myositis).
PAH screening: Annual echocardiography and DLCO; right heart catheterisation for confirmation.
Renal involvement: Less common than in SLE; membranous nephropathy is typical if it occurs.
Prognosis: Generally favourable 10-year survival (>80%), but PAH and pulmonary fibrosis worsen outcome.

Introduction & Australian Epidemiology

Mixed Connective Tissue Disease (MCTD) is a distinct overlap syndrome characterised by high-titre antibodies to U1-ribonucleoprotein (U1-RNP) and clinical features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis/dermatomyositis (IIM), and rheumatoid arthritis (RA).

It accounts for approximately 2-3% of systemic autoimmune rheumatic diseases in Australia. Prevalence is estimated at 1-2 per 100,000, with a strong female predominance (F:M ~9:1). Onset is typically in the second to third decade. Australian data mirror international trends, with Aboriginal and Torres Strait Islander populations potentially experiencing higher rates of severe organ involvement.

Anti-U1-RNP Antibodies

Anti-U1-RNP antibodies target the U1 small nuclear ribonucleoprotein complex. They are essential for diagnosis and are present in high titres (>1:1600 by immunofluorescence).

⚠️

Clinical note: Isolated low-titre anti-U1-RNP may occur in other conditions (e.g., SLE). A high titre in the appropriate clinical context defines MCTD.

Pattern: Typically a speckled ANA pattern. Anti-U1-RNP is often the sole extractable nuclear antigen (ENA).
Pathogenic role: Contributes to immune complex formation and interferon-alpha pathway activation.
Prognostic association: High titres correlate with Raynaud phenomenon, oesophageal dysmotility, and pulmonary hypertension.
Testing in Australia: Available via major pathology laboratories (e.g., Sonic, Laverty). MBS rebate applies for ENA testing (item 69494).

Overlap Features (SLE, SSc, IIM)

MCTD is a true overlap, with patients displaying features from at least two of the following diseases:

Disease Overlap	Typical Features in MCTD	Less Common in MCTD
SLE-like	Arthritis, serositis, lymphadenopathy, fever, leukopenia	Severe nephritis, CNS lupus, anti-dsDNA antibodies
SSc-like	Raynaud, sclerodactyly, swollen hands, oesophageal dysmotility, PAH	Diffuse cutaneous sclerosis (usually limited)
IIM-like	Proximal myalgia/weakness, elevated CK, myositis on EMG/MRI	Severe interstitial lung disease (ILD) compared to pure IIM

Features often evolve over time. The "Sharp syndrome" original description emphasised the triad of high-titre anti-U1-RNP, swollen hands, and Raynaud.

Raynaud Phenomenon & Swollen Hands

Present in >95% of patients. Often the earliest symptom, preceding other features by years.

Raynaud: Severe, triphasic (white-blue-red). May lead to digital pitting, ulceration, or gangrene. Assess with nailfold capillaroscopy (abnormal in ~60%, showing SSc-like pattern).
Swollen hands: "Puffy" or sausage-digit appearance due to non-pitting oedema. A key distinguishing feature from pure SSc or SLE.
Sclerodactyly: Often develops later, confined to fingers (acral sclerosis).

💡

Australian management: First-line Raynaud therapy: Amlodipine 5-10 mg daily (PBS General Benefit). For critical digital ischaemia: IV iloprost (requires authority prescription).

Pulmonary Hypertension

The leading cause of mortality in MCTD. Prevalence: 10-30% over disease course. Mechanism: predominantly pulmonary arterial hypertension (PAH, WHO Group 1) from vasculopathy.

🚨

Screening is mandatory: Annual echocardiography + DLCO (MBS item 11505). Refer for right heart catheterisation (RHC) if systolic PAP >40 mmHg or DLCO <60% predicted.

Symptoms: Exertional dyspnoea (often disproportionate to lung disease), syncope, chest pain.
Australian centres: RHC and PAH therapy initiation restricted to specialist centres (e.g., Royal Adelaide, Alfred, St Vincent's Sydney).
Treatment: Endothelin receptor antagonists (e.g., ambrisentan, PBS Authority Required), PDE5 inhibitors (sildenafil, PBS Authority), prostanoids (epoprostenol IV).

Diagnosis: Alarcon-Segovia Criteria

The most widely used criteria. Require both serological and clinical components.

1

Serological Criterion (Mandatory)

Anti-U1-RNP antibody positive at a titre ≥1:1600.

2

Clinical Criterion (≥3 of 6)

1. Oedema of hands
2. Synovitis
3. Myositis (biopsy or elevated CK)
4. Raynaud phenomenon
5. Acrosclerosis (sclerodactyly)
6. DLCO <70% of predicted

Diagnostic validation: The clinical features must derive from at least two of the diseases: SLE, SSc, IIM, RA.

Differentiating from Undifferentiated CTD

Undifferentiated connective tissue disease (UCTD) is a provisional diagnosis for patients with suggestive symptoms and serology who do not meet criteria for a defined CTD. MCTD is a specific, defined overlap.

Feature	MCTD	UCTD
Antibody	High-titre anti-U1-RNP (mandatory)	ANA often positive; anti-U1-RNP may be low-titre or absent
Overlap features	Clear features from ≥2 specific CTDs (SLE, SSc, IIM)	Non-specific (arthralgia, Raynaud, sicca) without definite pattern
Criteria	Meets Alarcon-Segovia or Sharp criteria	Does not meet criteria for any specific CTD
Evolution	Features stable or progress within MCTD phenotype	May evolve into a defined CTD (e.g., SLE) in 30% over 5 years

In practice, a patient with Raynaud, arthralgia, and a positive ANA but without anti-U1-RNP or specific organ involvement is classified as UCTD.

Investigations

Available

Full blood count, ESR, CRP

Leukopenia, thrombocytopenia, raised ESR common.

Available

Immunology: ANA, ENA, anti-U1-RNP titre, anti-dsDNA, complement

High-titre speckled ANA. Anti-U1-RNP positive. Anti-dsDNA usually negative. Complement often normal.

Available

Creatine kinase (CK), aldolase

Elevated in myositis overlap.

Available

Pulmonary function tests (PFTs) including DLCO

Annual screening. MBS item 11505.

Available

Echocardiography

Annual screening for PAH. Estimates RVSP.

Specialist

Right heart catheterisation (RHC)

Gold standard for PAH diagnosis. Mean PAP ≥20 mmHg, PAWP ≤15 mmHg.

Available

High-resolution CT chest

If ILD suspected. Findings often non-specific interstitial pneumonia (NSIP) pattern.

Available

Barium swallow / oesophageal manometry

For dysphagia. Shows reduced motility in distal two-thirds.

Available

Urinalysis, urine protein/creatinine ratio

Screen for glomerulonephritis (less common than in SLE).

Management Overview

Treatment is phenotype-driven, targeting the dominant clinical syndrome.

💊

Hydroxychloroquine

Plaquenil® · Antimalarial / Immunomodulator

Adult dose 200-400 mg daily (≤5 mg/kg actual weight)

Paediatric dose 3-5 mg/kg/day

Indication Arthralgia, fatigue, mild serositis, skin rash.

PBS status ✔ PBS General Benefit

💊

Methotrexate

Various · DMARD

Adult dose 7.5-25 mg SC/PO weekly + folic acid 5 mg weekly

Indication Inflammatory arthritis, myositis, skin disease.

PBS status ✔ PBS General Benefit

💊

Mycophenolate

CellCept® · Immunosuppressant

Adult dose 1-1.5 g BD

Indication ILD, renal disease, refractory skin/joint disease.

PBS status Authority Required

⚠️

Raynaud & Digital Ischaemia: First-line: Amlodipine 5-10 mg daily. Critical ischaemia: IV iloprost (specialist use). Avoid beta-blockers.

Special Populations

🤰

Pregnancy

Risk: Increased flare risk (arthritis, rash). PAH contraindicates pregnancy.

Medications: HCQ safe. Stop methotrexate, mycophenolate at least 3 months pre-conception. Azathioprine, tacrolimus considered safe.

Monitoring: Multidisciplinary care (rheumatology, obstetrics, cardiology).

👶

Paediatrics

Rarity: MCTD is extremely rare in children; juvenile dermatomyositis is more common.

Consideration: Anti-U1-RNP may be present in overlap syndromes. Manage as per dominant phenotype with paediatric rheumatology.

🩺

Renal Impairment

Nephritis: Less common, but membranous nephropathy may occur. Treat with glucocorticoids + MMF or cyclophosphamide.

Dose adjustment: Reduce NSAID use. Adjust MMF if eGFR <25.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Limited specific data on MCTD prevalence in ATSI populations. However, systemic autoimmune diseases are significant contributors to morbidity.

Access to Specialist Care

Significant barriers in remote communities. Telehealth for rheumatology and cardiology follow-up is essential. Patient-assisted travel schemes (PATS) are critical.

Diagnosis Delay

Symptoms like Raynaud and arthralgia may be misattributed. Higher index of suspicion needed. Utilise local Aboriginal Medical Services (AMS) for screening.

Comorbidities

Higher background rates of cardiovascular disease, diabetes, and renal disease complicate management and drug monitoring.

Cultural Safety

Engage Aboriginal Health Workers/Practitioners. Ensure clear communication about chronic disease and medication adherence in culturally appropriate formats.

📚 References

1. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989;16(3):328-334.
2. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-159.
3. Cappelli S, Bellando Randone S, Martinović D, et al. "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012;41(4):589-598.
4. Reiseter S, Gunnarsson R, Corander J, et al. Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study. Arthritis Res Ther. 2017;19(1):284.
5. Gendi NST, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation: ten-year clinical and immunogenetic followup. Arthritis Rheum. 1995;38(2):259-266.
6. Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2017.
7. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework. Canberra: AIHW; 2023.
8. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119.
9. Tyndall AJ, Bannert B, Vonk M, et al. Causes and predictors of death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-1815.
10. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282.
11. Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol. 2011;7(5):282-289.
12. Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford). 2017;56(1):14-25.